Disclosed herein are methods of treating
cancer, said methods comprising administering a therapeutically effective amount of erdafitinib to a patient who has been diagnosed with
cancer and who harbors at least one
fibroblast growth factor receptor (FGFR) fusion selected from FGFR2-CCDC102A, FGFR2-CCDC147, FGFR2-ENOX1, FGFR2-GPHN, FGFR2-LCN10, FGFR2-PDE3A, FGFR2-RANBP2, FGFR3-ENOX1, FGFR3-TMEM247, IGSF3-FGFR1, RHPN2-FGFR1, and RRM2B-FGFR2. Also disclosed herein are methods of treating
cancer comprising: evaluating a biological sample from a patient who has been diagnosed with cancer and who harbors at least one FGFR
gene alteration, wherein the cancer is cholangiocarcinoma, high-grade
glioma,
pancreatic cancer, squamous non-small-
cell lung cancer (NSCLC), non-squamous NSCLC,
breast cancer,
colorectal cancer,
endometrial cancer, gastric cancer,
ovarian cancer, cancer of
unknown primary,
cervical cancer, squamous
cell head and neck cancer,
esophageal cancer, low-grade
glioma,
prostate cancer, salivary gland cancer,
basal cell carcinoma, thymic cancer,
small intestine adenocarcinoma,
hepatocellular carcinoma, microcystic adnexal
carcinoma, spinocellular
carcinoma, gastrointestinal
stromal tumor, or parathyroid carcinoma; and administering a therapeutically effective
dose of an FGFR inhibitor to the patient if at least one FGFR
gene alteration is present in the sample.